Associated Papers
Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study.
Tao K et al.
Cancer Science, 2026
41249692 (PubMed )
Supplement: CAS-117-522-s002.xlsx › Table_S4
Establishment and Characterization of Three Human Ocular Adnexal Sebaceous Carcinoma Cell Lines.
Lee SC et al.
International Journal of Molecular Sciences, 2024
Germline RUNX1 variants in paediatric patients in a French specialised centre.
Liu C et al.
Ejhaem, 2023
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P et al.
Frontiers in Oncology, 2023
36910641 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S8
Revision of RUNX1 variant curation rules.
Feurstein S et al.
Blood Advances, 2022
35764482 (PubMed )
Supplement: advancesADV2022008017-suppl1.pdf
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.
Pastore F et al.
Blood Advances, 2020
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Shi E et al.
Journal of Translational Medicine, 2016
27974047 (PubMed )
Supplement: 12967_2016_1075_MOESM3_ESM.xlsx › Table_S7
RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.
Koh CP et al.
Leukemia, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
23819521 (PubMed )
Supplement: 1471-2164-14-S3-S7-S1.xlsx › COSMIC
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.
Schnittger S et al.
Blood, 2011
Select a paper to view details